# a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

Study · id `cardio:ct-nct05922436` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05922436](<https://clinicaltrials.gov/study/NCT05922436>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05922436

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 378 participants.

## Technical summary

Registry record NCT05922436. Randomized; triple masking; primary purpose treatment. Start 2023-07-15 (anticipated); primary completion 2024-05-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 378 participants (planned count; ClinicalTrials.gov record NCT05922436, source copy `cardio:ctgov-nct05922436-2023-06-28`, retrieved 2026-10-26)
- Planned start: 2023-07-15 (anticipated) (ClinicalTrials.gov record NCT05922436, source copy `cardio:ctgov-nct05922436-2023-06-28`, retrieved 2026-10-26)
- Primary completion: 2024-05-24 (anticipated) (ClinicalTrials.gov record NCT05922436, source copy `cardio:ctgov-nct05922436-2023-06-28`, retrieved 2026-10-26)
- Completion: 2024-05-25 (anticipated) (ClinicalTrials.gov record NCT05922436, source copy `cardio:ctgov-nct05922436-2023-06-28`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05922436-2023-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
- Condition: Hypertensive Emergency
- Intervention (Drug): QLG2071
- Intervention (Drug): Cleviprex®
- Lead sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 027ce9b021f54a743329d4341b9140a8e389d85e875543a935b5374203566e42
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
